Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : APMP (formerly APM) -- Ignore unavailable to you. Want to Upgrade?

To: Rudy who wrote (11072)	5/6/1998 10:10:00 PM
From: Richard Haugland	Respond to of 13456

Rudy, there was an article today that the Entremed run-up could trigger a general rise in biotech stocks, which have risen only 8.5% this year compared to 15% for the S&P 500. While I hope this is true, virtually all of these companies are losing money (including ENMD) and it may be years before they make any. I have moved a lot to this area since I know the technology but am not making a lot in it. I hold some of the leading companies AFFX, MLNM, BCHE and SANG and have made some money day trading while the stocks mostly languish or cycle over a couple of dollars range. Of these four, only BCHE is actually making any money but the rest "show a lot of promise." Overall, I like your current picks of the oil industry for a distressed segment more than the biotech area. The oil industry seems like it can only go up in the next 6 to 12 months but I am only invested in PDS so far, with some success.